Precigen EPS $(0.39) Vs $(0.40) YoY; Cash, Cash Equivalents, Short-Term And Long-Term Investments Totaled $62.9M As Of December 31, 2023
Portfolio Pulse from Benzinga Newsdesk
Precigen reported a narrower EPS loss of $(0.39) compared to $(0.40) YoY, with cash and investments totaling $62.9M as of December 31, 2023. R&D expenses rose by $1.4M, while SG&A expenses decreased by $7.6M. Total revenues fell by $20.7M, largely due to a decrease in collaboration and licensing revenues. Other income increased by $8.5M, mainly from reduced interest expenses and higher interest income. A $10.4M impairment charge was recorded for the Exemplar subsidiary. Loss from continuing operations widened to $95.9M from $79.8M YoY.
March 19, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Precigen reported a slight improvement in EPS loss and a significant cash position, despite a drop in revenues and a notable impairment charge.
The slight improvement in EPS and the strong cash position could be seen positively by investors. However, the significant drop in revenues and the impairment charge related to the Exemplar subsidiary could raise concerns about future profitability and operational efficiency. The mixed financial results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100